Clinical Trials
13 trialsNCT05213884 2026-04-24
The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC
Chongqing University Cancer Hospital
Phase 2 Completed
NCT07432087 2026-02-25
Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 3 Not yet recruiting
NCT07400094 2026-02-10
NeoCamre-HN
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Not yet recruiting
NCT05156970 2025-07-31
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Completed
NCT04649476 2025-01-10
NEOPBOSCC
Hospital of Stomatology, Wuhan University
Phase 2 Completed
NCT06109207 2024-07-23
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
West China Hospital
Phase 1 Recruiting
NCT05798793 2024-04-02
NEOPCOSCC
Hospital of Stomatology, Wuhan University
Phase 3 Recruiting
NCT06170697 2023-12-20
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT05069857 2023-11-22
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT05611463 2022-11-10
CHANCE
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Unknown
NCT04826679 2021-04-01
Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
Sun Yat-sen University
Phase 2 Unknown
NCT04440917 2021-02-02
IMplus
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Unknown
NCT04399785 2020-05-22
Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC
West China Hospital
Phase 2 Unknown